Compare SRRK & CVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | CVCO |
|---|---|---|
| Founded | 2012 | 1965 |
| Country | United States | United States |
| Employees | 289 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.5B |
| IPO Year | 2018 | 1994 |
| Metric | SRRK | CVCO |
|---|---|---|
| Price | $40.03 | $495.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 1 |
| Target Price | $55.10 | ★ $550.00 |
| AVG Volume (30 Days) | ★ 1.1M | 156.5K |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.74 |
| EPS | N/A | ★ 18.55 |
| Revenue | N/A | ★ $2,142,713,000.00 |
| Revenue This Year | N/A | $14.66 |
| Revenue Next Year | $449.79 | $7.70 |
| P/E Ratio | ★ N/A | $26.90 |
| Revenue Growth | N/A | ★ 31.68 |
| 52 Week Low | $22.71 | $393.53 |
| 52 Week High | $49.82 | $713.01 |
| Indicator | SRRK | CVCO |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 30.22 |
| Support Level | $29.32 | $488.88 |
| Resistance Level | $42.54 | $498.36 |
| Average True Range (ATR) | 2.24 | 21.46 |
| MACD | -0.62 | -7.16 |
| Stochastic Oscillator | 1.77 | 5.18 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.